BETA: Please send your feedback!
Vanda Pharmaceuticals
VNDA:NAS
Biotechnology
—
SMALL cap
(—)
—
since start of 2022
—
About
Biotechnology
Founded 2002
Vanda Pharmaceuticals, Inc. is a global biopharmaceutical company, which focuses on the development and commercialization of innovative therapies to improve the lives of patients. It intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.
website
Headquarters
Executives
| Name | Title | Gender |
| H. Thomas Watkins, MBA | Chairman | Male |
| Chip Clark, MBA | Founder | Male |
| Argeris N. Karabelas, PhD | Founder | Male |
| Mihael Hristos Polymeropoulos, MD | President, Chief Executive Officer & Director | Male |
| James Patrick Kelly, CFA, MBA | Chief Financial Officer, Treasurer & Senior VP | Male |
| Richard L. Gulino | Secretary, Senior VP & General Counsel | Male |
Mindful Investing Summary
Vanda Pharmaceuticals - Competitors and Related Companies
How Vanda Pharmaceuticals stacks up to its peers in the Biotechnology industry or with competing business segments.
Vanda Pharmaceuticals
VNDA:NAS
Biotechnology
—
SMALL cap
(—)
—
since start of 2022
—
Paratek Pharmaceuticals
PRTK:NAS
Biotechnology
—
SMALL cap
(—)
—
since start of 2022
—
Pernix Therapeutics
PTX:NAS
Pharmaceuticals: Other
—
MICRO cap
(—)
—
since start of 2022
—
Titan Pharmaceuticals
TTNP:NAS
Biotechnology
—
MICRO cap
(—)
—
since start of 2022
—
Bristol-Myers Squibb
BMY:NYS
Pharmaceuticals: Major
—
MEGA cap
(—)
—
since start of 2022
—
Johnson & Johnson
JNJ:NYS
Pharmaceuticals: Major
—
MEGA cap
(—)
—
since start of 2022
—